Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01150448 · ClinicalTrials.gov registry record · Phase 1
A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia
A Phase 1 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 1
- Development phase
- 212
- Enrollment target
NCT01150448: Completed Phase 1 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT01150448 is a Phase 1 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 212 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (253% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01150448, a Phase 1 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 212 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long term safety of flexible doses (50 to 150 mg equivalent) of paliperidone palmitate in the treatment of patients with schizophrenia and to document the pharmacokinetics of paliperidone following fixed multiple intramuscular injections of paliperidone palmitate 150 mg eq.
Interventions
- DRUG Paliperidone palmitate Treatment A
- DRUG Paliperidone palmitate Treatment B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
What the finished NCT01150448 record still lists
NCT01150448 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (253% higher).
The record links to 0 conditions, and to 2 interventions - of which Paliperidone palmitate Treatment A is the first listed.
NCT01150448 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01150448 about?
NCT01150448 is a clinical study titled "A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia". The purpose of this study is to evaluate the long term safety of flexible doses (50 to 150 mg equivalent) of paliperidone palmitate in the treatment of patients with schizophrenia and to document the pharmacokinetics of paliperidone following fixed multiple intramuscular injections of paliperidone p...
What is the current status of trial NCT01150448?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 212 participants. The study started on 2007-09. Estimated completion is 2009-06.
What interventions are being tested in trial NCT01150448?
The interventions under investigation include: Paliperidone palmitate Treatment A (DRUG), Paliperidone palmitate Treatment B (DRUG).
Who is sponsoring clinical trial NCT01150448?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01150448's enrollment target sits among peer trials
212 245th of 2000 higher than 1,756 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia